| Quote
: |
黄树宏,李可欣,查旭山.银屑胶囊联合阿维A胶囊治疗寻常性银屑病临床疗效和安全性的Meta分析[J].湖南中医药大学学报英文版,2019,39(4):495-502.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 2055times Download 542times |
| 银屑胶囊联合阿维A胶囊治疗寻常性银屑病临床疗效和安全性的Meta分析 |
| 黄树宏,李可欣,查旭山 |
| (广州中医药大学第一临床医学院, 广东 广州 510405;广州中医药大学第二临床医学院, 广东 广州 510405;广州中医药大学第一附属医院, 广东 广州 510405) |
| 摘要: |
| 目的 系统评价银屑胶囊联合阿维A胶囊治疗寻常性银屑病的临床疗效和安全性。方法 检索数据库包括：PubMed、Embase、Cochrane图书馆、中国生物医学文献数据库、中国知网、维普、万方数据库等，关键词采用"疗效""银屑胶囊"和"银屑病"，定年限为2000年1月至2018年12月，由两位研究者按照纳入排除标准独立筛选文献，进行文献质量评估和数据提取，结果采用Rev Man 5.3软件进行Meta分析。结果 共纳入7篇文献，共涉及660例患者。Meta分析结果显示，在有效性方面，银屑胶囊联合阿维A胶囊治疗寻常性银屑病的临床疗效优于单用阿维A胶囊，其60 d治愈率和60 d有效率的OR值分别为：2.21（95% CI：1.53~3.17）和2.66（95% CI：1.86~3.79）；在PASI评分方面，银屑胶囊联合阿维A胶囊治疗寻常性银屑病的PASI评分低于单用阿维A胶囊（SMD=-0.93，95% CI：-1.23~-0.62）；在血清炎症因子指标方面，银屑胶囊联合阿维A胶囊治疗寻常性银屑病的血清炎症因子IL-4、IL-10水平均高于单用阿维A胶囊：IL-4（SMD=0.83，95% CI：0.01，1.66），IL-10（SMD=0.56，95% CI：0.28，0.84）；在安全性方面，除了鼻出血外，银屑胶囊联合阿维A胶囊治疗寻常性银屑病的眼干、皮肤干燥、毛囊炎、转氨酶升高、高脂血症等不良反应发生率均显著低于单用阿维A胶囊的情况。结论 银屑胶囊联合阿维A胶囊治疗寻常性银屑病安全有效，然而，确切结论有待于更多的高质量、多中心、大规模的随机对照研究证实。 |
| 关键词: 银屑胶囊 阿维A胶囊 寻常性银屑病 Meta分析 |
| DOI：10.3969/j.issn.1674-070X.2019.04.013 |
| Received:December 02, 2018 |
| 基金项目:国家自然科学基金资助项目（81573980） |
|
| Meta-analysis of the Efficacy and Safety of Yinxie Capsule Combined with Acitretin Capsule in the Treatment of Psoriasis Vulgaris |
| HUANG Shuhong,LI Kexin,ZHA Xushan |
| (First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China;Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China;The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China) |
| Abstract: |
| Objective To systematically evaluate the clinical efficacy and safety of Yinxie Capsule combined with acitretin capsule in the treatment of psoriasis vulgaris. Methods Databases including PubMed, Embase, the Cochrane library, CBM, VIP, Wanfang database, CNKI were retrieved with the keywords of "efficacy", "psoriasis vulgaris", "Yinxie capsule" for the paper published from January, 2000 to December, 2018. Two investigators screened the literature according to the inclusion and exclusion criteria independently and carried out the quality assessment and data extraction. The data were meta-analyzed by Reviewer Manager 5.3. Results A total of 7 studies with 660 participants were included. Meta-analysis showed that the efficacy of Yinxie Capsule combined with acitretin Capsule in the treatment of psoriasis vulgaris was superior to that of acitretin Capsule alone. The OR of 60-day cure rate and the 60-day effective rate were 2.21 (95% CI:1.53-3.17) and 2.66 (95% CI:1.86-3.79). In terms of the PASI score, Yinxie Capsule combined with acitretin Capsule treatment group was significantly lower than simple acitretin Capsule control group (SMD=-0.93, 95%CI:-1.23——0.62). In terms of the serum inflammatory factors, the IL-4, IL-10 level of Yinxie Capsule combined with acitretin Capsule treatment group was significantly higher than simple acitretin Capsule control group (IL-4:SMD=0.83, 95%CI:0.01, 1.66; IL-10:SMD=0.56, 95%CI:0.28, 0.84). In terms of safety, apart from the nose bleeding, the incidence of adverse reactions of dry eyes, dry skin, folliculitis, transaminase elevation and hyperlipidemia of the Yinxie Capsule combined with acitretin capsuletreatment group was significantly lower than simple acitretin Capsule control group. Conclusion Yinxie Capsule combined with acitretin Capsule in the treatment of psoriasis vulgaris show definite clinical efficacy with safety. However, exact conclusion would benefit from additional high-quality, multi-centre, large-scale RCT studies. |
| Key words: Yinxie Capsule acitretin Capsule psoriasis vulgaris Meta-analysis |
|
二维码（扫一下试试看！） |
|
|
|
|
